Searched for
SHEKHAR MANDE
Buy Tata Steel, target price Rs 180: JM FinancialJM Financial recommends a Buy for Tata Steel, setting a target price of Rs 180. Tata Steel, a large-cap company in the ferrous metals secto...- I-Sec maintains Buy on Tata Steel, keeps target price unchanged at Rs 180ICICI Securities maintains a Buy call on Tata Steel with a target price of Rs 180, citing the company's focus on cost reduction and value e...
- Buy Tata Steel, target price Rs 150: Axis SecuritiesAxis Securities recommends a buy for Tata Steel, setting a target price of Rs 150. The company's financials for the quarter ending December...
- Clinical trials of new BCG vaccine for TB to start soon, says former CSIR chiefAccording to the India TB Report 2022, the number of 'incident TB patients' (new and relapse cases) notified during 2021 stood at 19.3 lakh...
- Nallathamby Kalaiselvi becomes first woman director general of CSIRKalaiselvi has risen through the ranks in CSIR and had broken the proverbial glass ceiling by becoming the first woman scientist to head th...
- Neglected infectious diseases may be tomorrow's pandemic: Bharat Biotech chief Dr Krishna EllaBharat Biotech's Covaxin is credited to be India's first indigenous COVID-19 vaccine to be approved and administered to a sizeable populati...
- Mapping groundwater sources by CSIR will help in using it for drinking: Jitendra SinghJitendra Singh said the CSIR, along with National Geophysical Research Institute (NGRI), have undertaken high-resolution aquifer mapping an...
- People have to ensure there is no COVID-19 '3rd wave': CSIR DG Shekhar MandeSpeaking to reporters online on Sunday night, the head of the premier institution under the Union ministry of science and technology, said ...
- Bharat Biotech, Biovet, Sapigen Biologix sign collaborative research agreement with CSIR-IICTThe Master Collaborative Agreement (MCA) was signed here by Bharat Biotech International, Biovet, Sapigen Biologix with the IICT in the pre...
- COVID-19 crisis far from over; 3rd wave to be more dangerous: CSIR officialContinued collaboration across institutions was necessary to come out of the current situation as well as ward off catastrophic situations ...
- Samajwadi Party leader Ashutosh Sinha claims COVID-19 vaccine might cause impotencySinha also backed party chief Akhilesh Yadav after the latter had said that he would not get vaccinated against COVID-19.
- Coronavirus vaccine will be equally effective against new mutant of coronavirus: CSIR DGThe CSIR's Institute of Genomics and Integrative Biology (IGIB), Delhi and Centre for Cellular and Molecular Biology (CCMB), Hyderabad have...
- India's Foreign Ministry briefs 190 diplomatic missions on Covid response; vaccine developmentAs its vaccine development programme progressed, India organized training programmes on clinical trials for neighbouring countries in which...
- Countries with low GDP, poor sanitation had lower COVID-19 death rate: StudyThe findings can lead to exploration of "immune training with possibilities of microbiome therapies", said Dr Shekhar Mande, Director Gener...
- Cipla all set to launch Favipiravir drug for treatment of COVID patients: CSIRAn off-patent anti-viral drug, Favipiravir, originally discovered by Fuji Pharma in Japan, has shown promise in clinical trials for treatme...
- Airborne transmission of Covid possible, wear masks in enclosed spaces, cautions CSIRAmid recent acknowledgement from the World Health Organisation (WHO) over emerging evidence of airborne spread of the novel coronavirus, th...
- COVID-19: CSIR institute to conduct clinical trials of antiviral drug UmifenovirThe drug has a good safety profile and acts by preventing entry of viruses into human cells and also by priming the immune system, accordin...
- Herd immunity as COVID-19 strategy risky, countries must make timely interventions: CSIR DGHerd immunity is achieved when the majority of population becomes immune to an infectious disease, either because they have become infected...
- CSIR submits 53 genome sequences of coronavirus to global body; to share 450 more by May 15CSIR's Institute of Genomics and Integrative Biology (IGIB), Delhi, Centre for Cellular and Molecular Biology (CCMB), Hyderabad and Institu...
- 'Feluda': Made-in-India paper-based strip for rapid, mass testing for Covid-19A completely indigenous scientific invention, 'Feluda' has been designed for mitigating the ongoing Covid-19 situation and to cater to mass...
Load More
